Overview
Butyrate is an important metabolite produced by the gut microbiome and has been shown as a helpful therapy in ulcerative colitis. This is a feasibility study to determine the efficacy of butryate enemas in pediatric ulcerative colitis.
Description
butyrate enemas will be administered for 12 weeks to children ages 7 to 21 with mild to moderate ulcerative colitis to determine if butyrate therapy can help improve the clinical disease in those children. standard management of the disease will be performed during these 12 weeks including routine laboratory studies and endoscopy.
Eligibility
Inclusion Criteria:
- 7-21 years, mild to moderate ulcerative colitis
Exclusion Criteria:
- UC therapy within 4 weeks of study medication initiation
- infectious colitis, -pregnancy